Romidon

Quick links to important sections

Romidon

Method of action: Analgesic, Opioid

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Romidon

Property Description
Active ingredient Dextropropoxyphene
Form Capsule or Tablet (Oral forms)
Pharmacological class Opioid Analgesic (Weak Opioid)
General purpose Symptomatic relief of mild to moderate pain
Origin Synthetic Organic Compound

What is Romidon and Its Pharmacological Identity?

Romidon is a medication whose identity is defined by its active pharmaceutical ingredient, Dextropropoxyphene. It is recognized within medical literature as a synthetic opioid analgesic and a central nervous system depressant. The substance is chemically manufactured, a synthetic organic compound that modifies the brain's perception of pain signals. Dextropropoxyphene is classified as a controlled substance in many regions due to its action on the central nervous system. Its primary therapeutic focus is providing symptomatic relief for mild to moderate pain, making it clinically recognized for managing discomfort when non-opioid options are insufficient.


Composition and Pharmaceutical Forms of Dextropropoxyphene

The core of Romidon is the active ingredient, Dextropropoxyphene, which is primarily encountered in two salt forms—the hydrochloride salt or the napsylate salt—influencing its absorption and pharmaceutical formulation. Romidon is supplied in solid oral dosage forms, typically as a capsule or a tablet, intended for ingestion. The structural relationship of Dextropropoxyphene to methadone underscores its mechanism of action and placement within the opioid family. This chemical structure validates its function in engaging the body's natural pain pathways.


General Purpose: Analgesia and Secondary Effects

Romidon's general purpose is centered on providing relief from physical discomfort through a centralized action that reduces the perceived intensity of pain. As an opioid analgesic, Dextropropoxyphene achieves this by acting as a mu-opioid receptor agonist. Beyond pain management, the substance exhibits a valuable secondary antitussive property, meaning it also influences the cough reflex center in the brainstem, offering an ancillary benefit of suppressing troublesome coughing. This dual action profile, providing both pain relief and cough suppression, represents a differentiating factor when compared to pure non-opioid analgesics.

Regulatory References

  1. Propoxyphene overdose - MedlinePlus Medical Encyclopedia

What side effects are possible with Romidon?

Possible Side Effects and Safety Information

The official safety profile of Dextropropoxyphene (Romidon) is defined by its potential for serious adverse reactions, particularly cardiotoxicity and central nervous system (CNS) depression, which can be life-threatening.

Serious Adverse Reactions and Cardiac Risk

Official regulatory sources highlight the risk of fatal overdose and serious abnormal heart rhythms (cardiotoxicity). New safety data showed that the drug, even when used at recommended therapeutic doses, can cause significant changes to the heart’s electrical activity, including prolonged PR, QRS, and QT intervals. These ECG changes increase the risk of serious arrhythmias and sudden death.

Respiratory Depression is noted as the chief hazard from all opioid agonist preparations and occurs most frequently in elderly or debilitated patients, or when the medication is combined with other CNS depressants, including alcohol.

Adverse Reaction Scope

The most common adverse reactions documented in regulatory labeling include CNS-related effects such as drowsiness, dizziness, lightheadedness, and euphoria, alongside gastrointestinal issues like nausea, vomiting, and constipation. The substance also carries a risk of seizures and impaired mental abilities.

Population-Specific Safety Considerations

Safety data specifies heightened risks for certain populations:

  • Elderly Patients: This group is particularly susceptible to respiratory depression and proarrhythmic effects due to reduced clearance of the cardioactive metabolite, norpropoxyphene.
  • Hepatic or Renal Impairment: Clearance of the drug and its metabolite is reduced, leading to higher plasma concentrations and an increased risk of toxicity.

Safety-Related Restrictions

The regulatory label strictly defines conditions that serve as limitations for use, including known hypersensitivity, significant respiratory depression, paralytic ileus, or a history of suicidal ideation.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

An overdose of Romidon (Dextropropoxyphene) is documented by regulatory authorities as a severe, potentially fatal event requiring immediate medical attention. The clinical presentation is characterized by dual toxicity affecting the Central Nervous System (CNS) and the cardiovascular system.

Documented signs of overdose include profound CNS depression, leading to severe drowsiness, confusion, stupor, and eventual coma. Respiratory depression, which presents as slow or shallow breathing, and pinpoint pupils (miosis) are expected. Overdose carries a serious risk of fatal outcome due to the rapid onset of both respiratory arrest and severe cardiotoxicity.

The official labeling notes the potential for cardiac conduction abnormalities, such as QRS complex widening and prolonged QT intervals, which can lead to circulatory collapse. The risk of severe toxicity is increased when the substance is co-ingested with alcohol or other CNS depressants, and the risk of respiratory depression is noted to occur more frequently in elderly or debilitated patients.

When to Seek Urgent Help

Regulatory instructions are definitive: Seek immediate medical attention right away for any suspected overdose. Emergency medical care is required for symptoms such as difficulty breathing, unresponsiveness, or signs of heart rhythm changes, including dizziness or fainting. The narcotic antagonist Naloxone is available as the specific antidote to reverse the opioid effects. However, due to the cardiac risks, official protocols mandate intensive monitoring that includes continuous ECG tracing for an extended period, often up to 24 hours.

Therapeutic Uses of Romidon

Romidon is generally used in clinical practice for the symptomatic relief of mild to moderate pain, often applied in scenarios where additional management of discomfort is required. The medication is considered relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations. It may assist patients whose pain creates noticeable physiological strain. The medication is commonly used across conditions presenting with acute or disruptive episodes of physical discomfort, and is considered relevant for conditions presenting with systemic or localized discomfort, such as those associated with dental procedures, musculoskeletal issues, or postoperative recovery. It provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability during periods of heightened symptoms. The medication generally offers symptomatic relief for an irritating, dry cough that frequently clusters with other acute symptoms. This dual application supports multiple symptom-focused domains, contributing to easing the overall symptom load in relevant situations.


Quick Fact: Relief for Dual Symptoms

A secondary therapeutic domain for Romidon is relevant for easing non-productive coughing alongside the management of mild to moderate pain.

Eligibility and Restrictions for Use

This information details the officially documented restrictions and eligibility rules for using Romidon (romidepsin), based strictly on authoritative governmental regulatory documents.

Official Eligibility Restrictions

Classification Population and Restriction
Contraindicated Patients with known hypersensitivity to romidepsin or any component of the formulation.
Contraindicated Pregnant women, due to the potential for embryo-fetal toxicity.
Contraindicated Concomitant use with lefamulin.
Not Recommended Lactating women; Pediatric patients (safety and effectiveness not established).
Requires Dose Adjustment Patients with moderate or severe hepatic impairment must receive a reduced starting dose.
Requires Monitoring Patients with a history of significant cardiovascular disease, congenital long QT syndrome, or those taking QT-prolonging medicines must undergo close cardiovascular monitoring, including ECGs, and have potassium and magnesium levels confirmed to be within the normal range before each administration.

Females of reproductive potential must use effective contraception during and for a specified time after treatment, as Romidon may reduce the effectiveness of estrogen-containing contraceptives. Males with female partners of reproductive potential must also use effective contraception for a specified period after the final dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies clinically significant interactions for Romidon, primarily concerning agents that affect drug metabolism through the cytochrome P450 3A4 (CYP3A4) enzyme system, of which Romidon is a substrate. These constraints are documented to manage potential changes in Romidon exposure.


Interacting Agents and Constraints

Product Category / Specific Agent Interaction Relevance
Strong CYP3A4 Inducers (e.g., Rifampin) Avoid Use (Risk of decreased Romidon exposure/efficacy)
Strong CYP3A4 Inhibitors Monitoring Required (Risk of increased Romidon exposure/toxicity)
Warfarin or Coumarin Derivatives Procedural Constraint (Requires careful monitoring of PT/INR)

The regulatory label explicitly advises to avoid co-administration with strong CYP3A4 inducers, with Rifampin specifically listed as an example, as this interaction may decrease the body's concentration of Romidon. Conversely, when Romidon is co-administered with strong CYP3A4 inhibitors, the required constraint is close monitoring for toxicities resulting from increased drug exposure. For patients taking the anticoagulant Warfarin or related coumarin derivatives, a specific procedural requirement is in place, demanding careful monitoring of the patient's Prothrombin Time (PT) and International Normalized Ratio (INR). These interaction rules are non-advisory and are based on the documented pharmacokinetic or pharmacodynamic effects described in the official regulatory product information.

Mechanism of Action

Romidon's mechanism of action involves a multimodal approach by targeting distinct biochemical pathways that influence physiological signaling patterns. The drug engages three key mechanistic domains, leading to specific alterations in pathway signaling within the targeted systems.

Modulating Prostaglandin Synthesis

This domain focuses on enzyme-mediated signaling, specifically the inhibition of prostaglandin synthesis in the central nervous system (CNS). This modification of early molecular steps results in the attenuation of mediator activity, contributing to the regulation of central thermoregulatory pathways and afferent nociceptive signaling.


Antagonizing Histamine Receptors

Romidon acts within domains involving receptor-mediated signaling by blocking histamine H1-receptors. This action suppresses signaling sequences initiated by histamine, a mediator associated with inflammatory processes. The resulting physiological effect is a modulation of capillary permeability and microvascular leakage.


Activating alpha-Adrenergic Receptors

This domain utilizes agonist action on alpha-adrenergic receptors located on blood vessels. By engaging mechanisms that regulate vascular tone, Romidon modifies key pathways associated with the sympathetic nervous system. This leads to the physiological consequence of peripheral vasoconstriction and localized reduction in blood flow.

Dosage and Administration Information

Administration and Dosage Regimen

Romidon is administered exclusively by the oral route, available in both capsule (typically the 65 mg hydrochloride salt) and tablet (typically the 100 mg napsylate salt) forms. Both forms deliver an equivalent amount of the active substance. The medication is generally taken on an as-needed basis for symptomatic control. The standard procedure involves taking one dose (65 mg or 100 mg) every four hours, but the total intake must not exceed the officially documented maximum daily dose. Specifically, the daily intake should not surpass 390 mg for the hydrochloride salt or 600 mg for the napsylate salt. The solid oral forms are intended to be swallowed whole with a glass of water and may be taken with or without food.


Population-Specific Use and Discontinuation

Official usage instructions require a reduced total daily dosage for specific patient groups. This modification is advised for older adults and for individuals with documented hepatic or renal impairment. This dosage adjustment is a procedural requirement relating to how these populations process the medicine. For patients who have been on prolonged therapy, the official protocol for stopping the medication requires a gradual reduction (tapering) in the daily dose. Abrupt cessation is not the specified procedure; the dose should be systematically lowered, for instance, by 25% to 50% per day, to complete the treatment course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Romidon (Dextropropoxyphene)


Evidence for Symptomatic Relief of Mild to Moderate Pain

The research available for Dextropropoxyphene largely consists of single-dose, short-term Randomized Controlled Trials (RCTs) and systematic reviews that pool data from these trials. This research was studied for use in exploring how symptoms change over time for acute or episodic physical discomfort. Study populations often included adults experiencing outcomes related to physical discomfort, such as following surgical or dental procedures. These studies examined short-term symptom changes, exploring temporary physiological imbalance and patient-reported outcomes describing perceived discomfort.

Outcomes Studied and Comparators

The main outcomes researchers examined were measures of pain intensity difference and the amount of symptom change reported by participants over the first few hours after administration. Studies also examined the time until a participant sought additional medication. Research explored how symptoms evolved in the observed populations, with findings describing patterns observed in the studies, including measurements compared against those reported by a placebo group. However, when compared with standard non-opioid pain relievers, such as paracetamol (acetaminophen) taken at typical therapeutic doses, comparative evidence is lacking regarding its performance relative to other standard options. Data show patterns related to the observed symptom change in the studied populations.


Research on the Secondary Antitussive Property

Dextropropoxyphene was also studied for a secondary role related to the influence on the cough reflex. This characteristic was observed in some studies, which is relevant in trials assessing short-term or episodic symptom patterns. Research describes patterns related to its effect on the cough reflex. However, the available data are not as extensive as the evidence base for its analgesic application; the antitussive property was monitored in studies primarily exploring pain relief.


Long-Term Studies and Follow-up

The existing research provides limited information for long-term outcomes. Because most high-quality evidence is derived from studies conducted during periods of increased symptom activity and focusing on short-term symptom changes, follow-up durations were limited. Outcomes related to systemic or functional imbalance over many months or years are not well characterized in the existing evidence. Evidence contributes to understanding symptom patterns only over defined time intervals immediately following use, and evidence remains limited regarding sustained effects or durability.


Evidence in Special Populations

The initial body of research primarily applies to the general adult population. Data for certain groups, such as the elderly (older adults) and individuals with specific chronic comorbidities, remain insufficient. Research has explored the way the body processes Dextropropoxyphene in older adults, and findings suggest that the compound and its main metabolite may stay in the body for a longer duration. The results apply only to the populations studied, and specific data for subgroups are uncertain, reflecting limited information to characterize outcomes fully in these groups.


What is Still Uncertain About Romidon Research

The research highlights several areas where the evidence landscape is limited. The evidence quality varies across studies, and comparative evidence is lacking to firmly establish a benefit over standard, non-opioid pain relievers alone. A key research limitation is the limited evidence on its use and patterns of response in long-term treatment scenarios. Furthermore, subgroup findings are uncertain for many special populations, and research does not determine whether an individual will respond similarly to the group patterns observed in the trials. The evidence highlights what is known—and what is still uncertain—about this compound.

Frequently Asked Questions (FAQ)

Common questions about Romidon (FAQ)

Q: Is Romidon a type of painkiller or something else?

A: Romidon is classified as an opioid analgesic, meaning its primary purpose is to provide symptomatic relief for mild to moderate pain. However, official information also notes that the active substance has a secondary antitussive property, which means it can also act as a cough suppressant.

Q: How quickly does Romidon usually start working?

A: According to the drug's pharmacokinetics data, the active substance reaches its highest concentration in the bloodstream approximately 2 to 2.5 hours after you take an oral dose. The time when peak concentrations are reached is often relevant to when the effects of the medication are maximized.

Q: Are there any common supplements that should be avoided while taking Romidon?

A: Regulatory documents advise caution regarding co-administration with products that are strong CYP3A4 inhibitors. While specific common supplements are not listed, this category includes many compounds that could increase the concentration of Romidon in the body, which may increase exposure to the drug and necessitate careful oversight.

Q: Can Romidon affect sleep patterns?

A: Yes, Romidon is known to have an effect on the central nervous system. Common adverse reactions listed in the official product information include drowsiness, sedation, and lightheadedness. These effects can influence your level of alertness and, consequently, your sleep/wake cycle.

Q: Is it normal to feel a bit dizzy when first starting Romidon?

A: Dizziness and lightheadedness are listed among the most frequent adverse reactions reported by patients taking this medication. Because these are frequently reported adverse reactions, they may be experienced early in the course of treatment.

Q: How long does Romidon stay in your system after stopping it?

A: Official pharmacokinetic data provide half-life information to estimate how long the drug remains in the system. The active substance has a half-life of 6 to 12 hours. However, its major active metabolite (norpropoxyphene), which is also known to be active, has a significantly longer half-life of 30 to 36 hours.

Q: Can Romidon be taken by people who have high blood pressure?

A: Regulatory information indicates that Romidon may cause or worsen hypotension (low blood pressure), especially when moving quickly from a sitting or lying position. The risk of developing or worsening hypotension is a factor considered for individuals with pre-existing blood pressure conditions.

Q: Does Romidon interact with alcohol, even in small amounts?

A: Yes, official warnings strongly caution against combining Romidon with alcohol. Both are central nervous system (CNS) depressants, and combining them can lead to serious, life-threatening CNS-additive effects.

Q: How often do people usually need to take Romidon?

A: The medication is intended for use on an as-needed basis to manage pain symptoms, with the standard frequency being approximately every four hours. The total daily intake is restricted and must not exceed the documented maximum dose.

Q: What happens if you miss a dose of Romidon?

A: Regulatory medication guides include specific instructions for addressing missed doses, generally involving taking the dose when remembered unless it is near the next scheduled time. The guides emphasize that a double dose should not be taken.

Q: Can Romidon be crushed or split if it's a tablet?

A: No. The official dosage and administration instructions state that the solid oral forms (capsules and tablets) are intended to be swallowed whole with a glass of water. The drug's official formulation requires that tablets and capsules be swallowed whole and intact.

Q: Are there specific foods that can interfere with how Romidon works?

A: The official product information notes that the medication can be taken with or without food. However, grapefruit juice is specifically noted in regulatory information to have a potential drug interaction.

Q: Do people develop a tolerance to Romidon over time?

A: Yes, due to its classification as a narcotic, the repeated and regular administration of Romidon can lead to the development of tolerance and physical dependence over time.

Q: What should I do if I suspect an allergic reaction to Romidon?

A: Official safety documents list signs of an allergic reaction (such as difficulty breathing, swelling, or hives) as serious adverse reactions. These are serious events that must be addressed.

Q: Is it true that Romidon requires regular blood work to monitor its effects?

A: The official label does not mandate general 'blood work.' However, for patients at risk of heart problems, close cardiovascular monitoring is required, including ECGs and checking potassium and magnesium levels to ensure they are within the normal range before administration.

Q: Why is Romidon sometimes prescribed for conditions other than its main use?

A: The drug's primary use is for pain relief. However, official sources recognize that it also possesses a secondary antitussive property (cough suppressant), which may explain its use in other contexts.

Q: How long before the full benefit of Romidon is typically felt?

A: While the drug's peak concentration is reached within 2.5 hours, in scenarios involving repeated administration, plasma concentrations build up. Official pharmacokinetics data show that a consistent, stable level (known as a plateau) is reached after approximately the ninth dose (about 48 hours).

Q: Can Romidon cause mood changes or depression?

A: The regulatory product information lists central nervous system effects such as euphoria (intense feeling of well-being), dysphoria (ill-being), and confusion as possible adverse reactions. Severe depression is also listed among the symptoms associated with an overdose.

Q: What is the current scientific consensus on Romidon's efficacy?

A: Studies, typically single-dose and short-term, show evidence supporting the drug's role in the symptomatic relief of mild to moderate pain. However, the research also notes a limitation: there is a lack of comparative evidence to firmly establish its benefit over standard, non-opioid pain relievers alone.

Q: Is Romidon available as a generic drug?

A: Yes, the active ingredient, Dextropropoxyphene, is listed in international regulatory databases as being available under multiple brand names and numerous generic formulations.

Q: What are the typical storage instructions for Romidon?

A: Official guidance mandates that Romidon be stored in a cool, dry place and kept in its original, tightly closed container. The medication must be stored out of the sight and reach of children.

Q: Are headaches a common initial side effect of Romidon?

A: Yes, headache is listed among the adverse reactions reported in clinical surveys. It is listed among the other adverse reactions reported in clinical surveys.

Q: What should I avoid completely while taking Romidon?

A: Regulatory warnings indicate that concomitant use with alcohol, strong CYP3A4 inducing agents (such as Rifampin), and the drug lefamulin should be avoided due to the risk of serious interactions.

Q: Is Romidon safe to take during pregnancy (high-level, non-advisory)?

A: No, Romidon is listed as contraindicated (should not be used) in pregnant women. This is due to the potential risk of embryo-fetal toxicity as documented in the official safety information.

Q: Does Romidon affect birth control pills?

A: Yes, official restrictions warn that Romidon may reduce the effectiveness of estrogen-containing contraceptives. Regulatory documents state that use of effective non-hormonal contraception is required during treatment and for a specified period after the final dose.

Q: Does taking Romidon mean I can't drive or operate machinery?

A: Regulatory warnings state that Romidon may cause side effects like sleepiness and dizziness. These effects may impair the mental and physical abilities required to perform potentially hazardous tasks, such as driving a car or operating machinery.

Q: Does Romidon cause dry mouth or changes in taste?

A: Yes, dry mouth is specifically listed among the common side effects reported with this medication.

Q: Is Romidon a controlled substance?

A: Yes, the active ingredient is classified as a Schedule IV narcotic under the U.S. Controlled Substances Act and similar international regulations. This classification is due to its effects on the central nervous system and its potential for abuse and dependence.

Q: Can Romidon be taken on an empty stomach?

A: Yes, the official dosage and administration instructions state that the medication may be taken with or without food.

Q: Is Romidon generally safe for older adults (seniors)?

A: Official usage instructions state that a reduced total daily dosage is advised for older adults. This modification is due to this population's increased susceptibility to adverse effects, such as respiratory and cardiac issues, and slower drug clearance.

Q: What are some serious but rare side effects of Romidon I should watch out for?

A: Official regulatory documents highlight the potential for serious adverse reactions. These include the risks of fatal overdose, severe respiratory depression, and life-threatening abnormal heart rhythms (cardiotoxicity), which can occur even at recommended doses.

How should Romidon be stored and disposed of?

Romidon (Dextropropoxyphene) must be stored and disposed of according to strict official requirements due to its nature as a controlled substance. The medicine should be kept in a cool, dry place and stored only in its original, tightly closed container to ensure stability and integrity. To prevent accidental ingestion, Romidon must be stored out of the sight and reach of children.

For disposal, regulatory guidance mandates two options for unused or expired medicine. The most effective method is using a drug take-back program. If this is unavailable, the product must be removed from its container, mixed with an undesirable substance (such as used coffee grounds), placed in a sealed bag, and thrown into the household trash. The medicine must not be flushed down the toilet or allowed to enter the water supply.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Romidon found in:

A-Z Index: